Skip to content
Open access

Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study

Aug 2026 · Frontiers in Medicine · Vol 13 · 0 citations · 30 references
Medicine

TL;DR

Serum miRNAs offer novel predictive and concurrent biomarker signals during biologic induction in Crohn’s disease, providing information complementary to faecal calprotectin.

Abstract

Background and aims Validated biomarkers of biologic response in Crohn’s disease (CD) are lacking. We assessed whether serum microRNAs (miRNAs) track disease activity and predict outcomes during biologic induction in CD. Methods Thirty-nine adults with active CD initiating infliximab (n = 20) or vedolizumab (n = 19) and 10 controls were studied at a single centre. Serum was sampled at the first and fourth infusions. Six target miRNAs were qPCR-quantified and normalised to the geometric mean of miR-93-5p and miR-425-5p. Harvey–Bradshaw Index, C-reactive protein, faecal calprotectin and Simple Endoscopic Score for CD were recorded at baseline, post-induction and 12 months. Four pre-specified analysis families were tested with false discovery rate (FDR) correction for multiple testing. This was a single-centre, exploratory, hypothesis-generating study. Results miR-21-5p and miR-146b-5p were significantly reduced in CD versus controls (q < 0.05). Baseline miR-146b-5p inversely predicted post-induction CRP independently of baseline disease severity (partial r = −0.46, p = 0.010), supporting it as a candidate severity-independent predictor of biochemical response. Post-induction miR-424-5p strongly tracked concurrent inflammation (faecal calprotectin: Spearman ρ = +0.52, q = 0.004; CRP: ρ = +0.44, q = 0.030), these associations remained significant after adjustment for baseline disease severity, after leave-one-out removal of single patients, and under single-reference normalisation. An exploratory post-hoc analysis linked treatment-induced miR-106a-5p upregulation to penetrating (Montreal B3) disease (permutation p = 0.019). Conclusion Serum miRNAs offer novel predictive (baseline miR-146b-5p and miR-106a-5p) and concurrent (post-induction miR-424-5p) biomarker signals during biologic induction in CD, providing information complementary to faecal calprotectin. Prospective independent validation is warranted before clinical translation.

Read PDF

Similar papers

Open access Sep 2026

Early Prediction of Primary Non-Response to Infliximab in Crohn’s Disease Using Routinely Available Clinical and Week 2 Laboratory Indicators: A Two-Center Real-World Cohort Study

Purpose Primary non-response (PNR) occurs in a subset of patients with Crohn’s disease (CD) after infliximab (IFX) induction therapy and remains challenging to identify early. This study aimed to develop and perform preliminary external validation of an early PNR risk stratification model using routinely available clin...

Mei-Hua Zhao, Dong-Yao Zhao, Li Geng et al. · 0 citations
Open access Sep 2026

The Impact of Infliximab Trough Level and Anti-Drug Antibody on Clinical Outcomes in Crohn's Disease Patients: A Cross-Sectional Study in Iraq

Introduction: Primary non-response and secondary loss of response, often mediated by the development of anti-drug antibodies (ADAs), limit treatment efficacy. Therapeutic drug monitoring (TDM) is gaining importance in optimizing infliximab therapy by correlating drug levels with clinical outcomes. This study aimed to i...

Ahmad K. Al-Jalehawi, Mahmoud A. Alkindy, Muslim Alkafaji et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Upadacitinib was effective and well-tolerated in AT-experienced Crohn's disease, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

B. Barberio, F. D'Amico, L. Laterza et al. · 2 citations
Open access Sep 2026

Towards Precision Medicine in Inflammatory Bowel Diseases: Pharmacogenetic Predictors of Ustekinumab Effectiveness and Persistence

IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.

Ylenia Marino, M. Rottura, Claudia Ligresti et al. · 0 citations
Open access Sep 2026

Changes in circulating microRNAs and inflammatory proteins in children with celiac disease during the first year on a gluten-free diet.

BACKGROUND & AIMS In celiac disease (CD), mucosal recovery can only be assessed through biopsy, as current serological tests do not reliably reflect histological status or residual inflammation after gluten withdrawal. This limitation is particularly relevant in children, in whom invasive procedures are preferably avoi...

Gesala Perez-Junkera, Naroa Altolaguirre, A. Lasa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.